source
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutSanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as a potential blockbuster “would not represent a meaningful improvement” to exis…Fierce Biotech · 6d ago↗ source
- Early Alert: Percutaneous Catheter Issue from Boston ScientificENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during usefda medwatch · 6d ago↗ source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.